Chemomab Therapeutics (CMMB) holder Erik Otto reports 1.2% ADS ownership
Rhea-AI Filing Summary
Chemomab Therapeutics Ltd. investor Erik Otto filed an amended Schedule 13G reporting his beneficial ownership of the company’s American Depository Shares (ADSs). He reports beneficial ownership of 90,000 ADSs, each ADS representing twenty ordinary shares with no par value.
Based on 7,200,377 ADSs outstanding as of May 14, 2026, this position represents 1.2% of the class. Otto reports sole voting power and sole dispositive power over all 90,000 ADSs, with no shared voting or dispositive power. The holding is explicitly disclosed as ownership of 5 percent or less of the class.
Positive
- None.
Negative
- None.
Key Figures
ADSs beneficially owned: 90,000 ADSs
Ownership percentage: 1.2%
ADSs outstanding: 7,200,377 ADSs
+2 more
5 metrics
ADSs beneficially owned
90,000 ADSs
Amount beneficially owned by Erik Otto
Ownership percentage
1.2%
Percent of Chemomab ADS class owned by Erik Otto
ADSs outstanding
7,200,377 ADSs
ADSs outstanding as of May 14, 2026, as provided by issuer
Sole voting power
90,000 ADSs
Shares over which Erik Otto has sole voting power
Sole dispositive power
90,000 ADSs
Shares over which Erik Otto has sole dispositive power
Key Terms
beneficially owned, Sole Voting Power, Sole Dispositive Power, American Depository Shares, +1 more
5 terms
beneficially owned financial
"Amount beneficially owned: 90000"
Beneficially owned describes securities or assets where a person has the economic rights and control—such as the right to receive dividends and to direct voting—even if legal title is held in another name. Think of it like having the keys and using a car that’s registered to someone else: you get the benefits and make decisions. Investors care because beneficial ownership reveals who truly controls value and voting power, affecting corporate decisions and takeover dynamics.
Sole Voting Power financial
"Sole Voting Power 90,000.00"
Sole voting power is the exclusive right to cast votes attached to a shareholder’s stock without needing approval from anyone else. Like holding the only remote control for a TV, it lets that holder decide corporate matters such as board members, mergers, and policy changes, making it important to investors because it concentrates control and can strongly influence a company’s strategy and the value of its shares.
Sole Dispositive Power financial
"Sole Dispositive Power 90,000.00"
Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.
percent of class financial
"Percent of class: 1.2 %"
Percent of class is the portion of a specific category of securities—such as a company’s common shares, preferred shares, or a bond series—that takes part in or approves a corporate action (vote, consent, tender, etc.). Investors watch this number because it reveals how much support or opposition exists within that particular shareholder group; like counting how many members of a club back a proposal, it can determine whether a plan passes or how influence is distributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What percentage of Chemomab Therapeutics (CMMB) does Erik Otto report owning in this 13G/A?
Erik Otto reports owning 1.2% of Chemomab Therapeutics’ ADSs. This percentage is based on 7,200,377 ADSs outstanding as of May 14, 2026, as provided by the issuer.
How many Chemomab Therapeutics (CMMB) ADSs does Erik Otto beneficially own?
Erik Otto reports beneficial ownership of 90,000 American Depository Shares (ADSs) of Chemomab Therapeutics. He has sole voting and sole dispositive power over all 90,000 ADSs, with no shared power reported.
What class of Chemomab Therapeutics (CMMB) securities is covered in Erik Otto’s Schedule 13G/A?
The filing covers American Depository Shares (ADSs) of Chemomab Therapeutics Ltd., each ADS representing twenty ordinary shares with no par value, identified by CUSIP 36322Q107.
Does Erik Otto’s Chemomab (CMMB) position exceed 5% ownership of the class?
No. Erik Otto’s position is explicitly reported as 1.2% of the class, and the filing confirms Ownership of 5 percent or less of a class, keeping him below the 5% threshold.